Lannett Holdings

Lannett is a pharmaceutical company that specializes in the development, manufacturing, and distribution of generic prescription drugs. The company's extensive portfolio covers a broad range of therapeutic areas, including pain management, cardiovascular health, and endocrinology, with products available in various dosage forms such as oral solids, liquids, and topicals. In 2023, Lannett completed a financial restructuring that transitioned the company from a public entity to a private one, allowing it to focus on long-term growth initiatives. A major component of its current strategy is the development of biosimilars, specifically a biosimilar insulin glargine product developed in partnership with HEC Pharm. Lannett maintains significant manufacturing and R&D facilities in the United States, ensuring a robust supply chain for its generic offerings.